LSI USA '25 Almost at Capacity: Register Today arrow-icon
Mar 21, 2025

The Weekly Recap 3/21/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

social-facebooksocial-xsocial-linkedin
The Weekly Recap 3/21/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

  1. Brainomix

  2. Curespec

  3. eCential Robotics

  4. LEADOPTIK

  5. Madison Scientific

  6. MY01

  7. Quibim

  8. Relief

  9. RevBio

  10. Theradaptive

Weekly Recap 16_9 - 03.21.2025

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $25M in new funding, announce regulatory milestones, appoint new board members, and much more as we wind down LSI USA ‘25 in Dana Point, CA, and gear up for LSI Asia ‘25 in Singapore (June 10-13).

Brainomix

Completed a £14M ($18M) Series C round to expand its AI-powered stroke and lung fibrosis imaging solutions in the United States. The funding will also be used to further develop its technology portfolio in new areas for faster diagnosis and improved access to life-saving treatments.

Curespec

Appointed LSI Alumni Avner Geva to its Board of Directors as the company advances its Nephrospec system for hypertension and chronic kidney disease. The CE-marked electro-hydraulic acoustic (eHAT) technology aims to reduce blood pressure, improve kidney function, and delay dialysis.

eCential Robotics

Announced FDA clearance of the PERLA App for use with the Op.n robotic navigation platform in collaboration with Spineart. This approval enhances procedural precision and workflow efficiency in robotic-assisted spine surgery.

LEADOPTIK

Initiated a research collaboration with Stanford Medicine to enhance lung cancer biopsy procedures through AI-powered real-time optical imaging. The partnership aims to improve diagnostic precision and patient outcomes in interventional pulmonology.

Madison Scientific

Secured $7M in seed funding to advance its SmartShunt System for hydrocephalus treatment. The funds will be allocated to expanding the Madison Scientific team, advancing preclinical testing, and further developing prototypes for the company’s innovative SmartShunt Hydrocephalus Management System.

MY01

Received FDA 510(k) clearance and Breakthrough Designation for Perfusion Pressure on its mobile app. The new feature improves diagnosis of compartment syndrome and acute limb ischemia, enhancing patient care with objective, data-driven insights.

Quibim

Received FDA 510(k) clearance for QP-Prostate CAD, its AI-powered lesion detection solution for prostate cancer. The technology accelerates image processing and enhances diagnostic accuracy to support early detection and treatment.

Relief

Appointed Michael Kujak and Steffen Hovard to its Board of Directors and established a Medical Advisory Board led by Dr. Dean Elterman. These developments highlight Relief’s efforts to strengthen leadership, regulatory expertise, and market positioning by adding experienced executives and advisors.

RevBio

Initiated a pivotal clinical trial in Europe for its dental implant stabilization product, TETRANITE. The study aims to achieve CE-marking approval and allow commercial sales in Europe, advancing dental care with improved implant stability.

Theradaptive

Appointed Jeffrey W. Dunn to its Board of Directors to support its targeted protein therapeutics platform. His expertise will help guide the company’s efforts to capture the $4B bone graft market and expand applications in regenerative medicine.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.